TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy
Brief Summary: The primary objective of the study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally (IT) to participants with infantile-onset with infantile-onset spinal muscular atrophy (SMA). The secondary objective of the study is to examine the safety and tolerability of nusinersen administered intrathecally to participants with infantile-onset SMA.


Options:
A: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
B: Arm Label: Cohort 1a; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine, Drug: Placebo | Arm Label: Cohort 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): Cohort 1a, Cohort 1b, Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1a
C: Arm Label: Olesoxime; Type: EXPERIMENTAL; Interventions: Drug: Olesoxime | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olesoxime; Assigned to Arm(s): Olesoxime | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy
Brief Summary: The primary objective of the study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally (IT) to participants with infantile-onset with infantile-onset spinal muscular atrophy (SMA). The secondary objective of the study is to examine the safety and tolerability of nusinersen administered intrathecally to participants with infantile-onset SMA.


Options:
A: Arm Label: Cohort 1a; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine, Drug: Placebo | Arm Label: Cohort 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): Cohort 1a, Cohort 1b, Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1a
B: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen
C: Arm Label: nusinersen; Type: EXPERIMENTAL; Interventions: Drug: nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: nusinersen; Assigned to Arm(s): nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure
D: Arm Label: Nusinersen; Type: EXPERIMENTAL; Interventions: Drug: Nusinersen | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham procedure | Intervention Type: DRUG; Name: Nusinersen; Assigned to Arm(s): Nusinersen | Intervention Type: PROCEDURE; Name: Sham procedure; Assigned to Arm(s): Sham procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial on Home Telemonitoring for the Management of Metabolic and Cardiovascular Risk in Individuals With Type 2 Diabetes
Brief Summary: The primary goal is to evaluate whether a home telehealth system that enables the participant to monitor their body weight, blood glucose values and blood pressure values, associated with remote educational support and feedback to the general practitioner, can improve metabolic control and overall cardiovascular risk in individuals with type 2 diabetes mellitus (T2DM), as compared to usual practice.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group
B: Arm Label: Geriatric diabetes team intervention group; Type: EXPERIMENTAL; Interventions: Other: Intervention for age specific barriers to self care | Arm Label: Attention Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Intervention for age specific barriers to self care; Assigned to Arm(s): Geriatric diabetes team intervention group
C: Arm Label: Telemedicine system; Type: EXPERIMENTAL; Interventions: Device: Home telehealth system | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Home telehealth system; Assigned to Arm(s): Telemedicine system
D: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications
Brief Summary: A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema following retinal vein occlusion (RVO) or due to chorioidal neovascularization following pathologic myopia (mCNV) with repeated intravitreal injections of Lucentis® (Ranibizumab) including optional OCT monitoring over a 24 months observational period under real life conditions.


Options:
A: Arm Label: Cohort with routine OCT monitoring; Type: N/A; Interventions: N/A | Arm Label: Cohort without routine OCT monitoring; Type: N/A; Interventions: N/A
B: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.3 mg | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab 0.5 mg | Arm Label: Sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab 0.3 mg; Assigned to Arm(s): Ranibizumab 0.3 mg | Intervention Type: DRUG; Name: Ranibizumab 0.5 mg; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection
C: Arm Label: Sham Control; Type: SHAM_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Macugen; Type: EXPERIMENTAL; Interventions: Drug: Macugen | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Sham Control | Intervention Type: DRUG; Name: Macugen; Assigned to Arm(s): Macugen
D: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications
Brief Summary: A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema following retinal vein occlusion (RVO) or due to chorioidal neovascularization following pathologic myopia (mCNV) with repeated intravitreal injections of Lucentis® (Ranibizumab) including optional OCT monitoring over a 24 months observational period under real life conditions.


Options:
A: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
B: Arm Label: Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab
C: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
D: Arm Label: Cohort with routine OCT monitoring; Type: N/A; Interventions: N/A | Arm Label: Cohort without routine OCT monitoring; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.
Brief Summary: This research study is evaluating a drug called isoquercetin to prevent venous thrombosis (blood clots), in participants who have pancreas, non small cell lung cancer or colorectal cancer.


Options:
A: Arm Label: Semuloparin; Type: EXPERIMENTAL; Interventions: Drug: Semuloparin sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for semuloparin) | Intervention Type: DRUG; Name: Semuloparin sodium; Assigned to Arm(s): Semuloparin | Intervention Type: DRUG; Name: Placebo (for semuloparin); Assigned to Arm(s): Placebo
B: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
C: Arm Label: Cohort A - Isoquercetin; Type: EXPERIMENTAL; Interventions: Drug: Isoquercetin | Arm Label: Cohort B - Isoquercetin; Type: EXPERIMENTAL; Interventions: Drug: Isoquercetin | Intervention Type: DRUG; Name: Isoquercetin; Assigned to Arm(s): Cohort A - Isoquercetin, Cohort B - Isoquercetin
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo drug | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo drug; Assigned to Arm(s): Placebo drug

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does the Addition of Growth Hormone to the Invitro Fertilization/ Intracytoplasmic Sperm Injection Antagonist Protocol Improve Outcome in Poor Responders? A Randomized Controlled Trial
Brief Summary: The effect of use of the growth hormone with antagonist protocol on the outcome of the IVF/ICSI cycles in poor responders.


Options:
A: Arm Label: The Long protocol; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Arm Label: The Short protocol; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Arm Label: The Antagonist protocol; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Arm Label: The Microflare protocol; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Intervention Type: DRUG; Name: Growth hormone (Norditropin, Novo nordisk); Assigned to Arm(s): The Antagonist protocol, The Long protocol, The Microflare protocol, The Short protocol
B: Arm Label: Long + Growth hormone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Growth hormone | Arm Label: Long protocol only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Growth hormone; Assigned to Arm(s): Long + Growth hormone
C: Arm Label: Microflare and growth hormone; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Arm Label: Microflare protocol alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Growth hormone (Norditropin, Novo nordisk); Assigned to Arm(s): Microflare and growth hormone
D: Arm Label: Antagonist and Growth hormone; Type: EXPERIMENTAL; Interventions: Drug: Growth Hormone | Arm Label: Antagonist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Growth Hormone; Assigned to Arm(s): Antagonist and Growth hormone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients
Brief Summary: REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients, is a multicenter, randomized, attention-controlled, single-blind trial designed to examine the hypothesis that, in addition to standard care, a novel, tailored, progressive, multi-domain rehabilitation intervention administered to older patients with acute decompensated heart failure (ADHF) beginning early during hospitalization and continuing for 12 weeks will improve physical function and key clinical outcomes, including the rate of rehospitalization.


Options:
A: Arm Label: Exercise Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Dietary Intervention; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Dietary Intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Other: Attention Control | Arm Label: Diet and Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise, Behavioral: Diet and exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Diet and Exercise, Exercise Training | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Intervention; Assigned to Arm(s): Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Diet and exercise; Assigned to Arm(s): Diet and Exercise | Intervention Type: OTHER; Name: Attention Control; Assigned to Arm(s): Attention control
B: Arm Label: Attention Control; Type: OTHER; Interventions: Behavioral: Attention Control | Arm Label: multi-domain rehabilitation intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: multi-domain rehabilitation intervention | Intervention Type: BEHAVIORAL; Name: multi-domain rehabilitation intervention; Assigned to Arm(s): multi-domain rehabilitation intervention | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): Attention Control
C: Arm Label: Non coronary patients (NC); Type: N/A; Interventions: N/A | Arm Label: Coronary patients (C); Type: N/A; Interventions: N/A
D: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Brief Summary: The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress


Options:
A: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low impact exercise | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low impact exercise; Assigned to Arm(s): 2
C: Arm Label: Be Well At Work intervention + IC; Type: EXPERIMENTAL; Interventions: Other: Veterans Work and Health Initiative | Arm Label: Integrated Care Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Veterans Work and Health Initiative; Assigned to Arm(s): Be Well At Work intervention + IC
D: Arm Label: Brexpiprazole + ADT; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole +ADT | Arm Label: Placebo + ADT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Placebo + ADT | Intervention Type: DRUG; Name: Brexpiprazole +ADT; Assigned to Arm(s): Brexpiprazole + ADT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress
Brief Summary: The purpose of this study is to assess the tolerability, safety, and efficacy of brexpiprazole (2.0 mg/day) as adjunctive therapy in adult subjects with a diagnosis of MDD with and without anxious distress


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole+ ADT | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo+ ADT | Intervention Type: DRUG; Name: Aripiprazole+ ADT; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo+ ADT; Assigned to Arm(s): A2
B: Arm Label: lithium plus usual care; Type: EXPERIMENTAL; Interventions: Drug: lithium | Arm Label: usual care without lithium therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: usual care | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): lithium plus usual care | Intervention Type: DRUG; Name: usual care; Assigned to Arm(s): usual care without lithium therapy
C: Arm Label: Brexpiprazole + ADT; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole +ADT | Arm Label: Placebo + ADT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Placebo + ADT | Intervention Type: DRUG; Name: Brexpiprazole +ADT; Assigned to Arm(s): Brexpiprazole + ADT
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Vilazodone 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone, Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Vilazodone 40 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone, Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Citalopram 40 mg/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo to vilazodone, Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Placebo to citalopram; Assigned to Arm(s): Placebo, Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Placebo to vilazodone; Assigned to Arm(s): Citalopram 40 mg/day, Placebo, Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram 40 mg/day

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Inpatient Psychotherapeutic Treatment With Online Self Help in a Randomised Controlled Trial: Acceptance and Efficacy
Brief Summary: The purpose of this study is to determine the acceptance and efficacy of the online self-help program deprexis® for depressed patients in reducing the clinical symptoms of their depression. The patients of the experimental group use deprexis® for 90 days, the patients of the placebo group receive weekly online information about depression for 90 days as well. Both groups receive their treatment in addition to their regular inpatient psychosomatic treatment and as an aftercare intervention.The investigators hypothesize that the online self-help group achieves a greater reduction of depression compared to the control group.


Options:
A: Arm Label: Individual Placement and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support | Arm Label: Ordinary employment schemes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary employment schemes | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support; Assigned to Arm(s): Individual Placement and Support | Intervention Type: BEHAVIORAL; Name: Ordinary employment schemes; Assigned to Arm(s): Ordinary employment schemes
B: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg
C: Arm Label: deprexis®; Type: EXPERIMENTAL; Interventions: Other: deprexis® | Arm Label: Information; Type: PLACEBO_COMPARATOR; Interventions: Other: Information | Intervention Type: OTHER; Name: deprexis®; Assigned to Arm(s): deprexis® | Intervention Type: OTHER; Name: Information; Assigned to Arm(s): Information
D: Intervention Type: DRUG; Name: DVS-233 SR; Assigned to Arm(s): N/A

Answer: C